Get the Stockscreener App
8.50
1.88%
0.26
Lexeo Therapeutics Inc stock is traded at $8.50, with a volume of 173.05K.
It is up +1.88% in the last 24 hours and up +62.07% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$8.24
Open:
$8.36
24h Volume:
173.05K
Relative Volume:
0.26
Market Cap:
$459.01M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-3.001
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
+29.75%
1M Performance:
+62.07%
6M Performance:
+323.99%
1Y Performance:
+2.50%
1-Day Range:
$8.31
$8.50
1-Week Range:
$7.75
$8.88
52-Week Range:
$1.45
$11.72
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
8.50 | 444.97M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.42 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.18 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.17 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Will Lexeo Therapeutics Inc. stock outperform Nasdaq indexRate Cut & Fast Entry High Yield Tips - newser.com
Best data tools to analyze Lexeo Therapeutics Inc. stockWeekly Market Outlook & Free Weekly Chart Analysis and Trade Guides - newser.com
Leerink Partnrs Issues Positive Forecast for LXEO Earnings - Defense World
Lexeo Therapeutics, Inc.: A Deep Dive (NASDAQ:LXEO) - Seeking Alpha
How to monitor Lexeo Therapeutics Inc. with trend dashboardsMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Smart tools for monitoring Lexeo Therapeutics Inc.’s price action2025 Pullback Review & Daily Stock Trend Reports - newser.com
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease - streetwisereports.com
Analyzing recovery setups for Lexeo Therapeutics Inc. investorsJobs Report & Verified Chart Pattern Signals - newser.com
Biotech Firm Uncovers Breakthrough Gene Therapy in New York - streetwisereports.com
How to integrate Lexeo Therapeutics Inc. into portfolio analysis toolsJuly 2025 Price Swings & High Conviction Trade Alerts - newser.com
Is a relief rally coming for Lexeo Therapeutics Inc. holdersWeekly Profit Summary & Free Weekly Watchlist of Top Performers - newser.com
Lexeo Therapeutics Announces Progress in FDA Discussions and Positive Interim Data for LX2006 - TradingView
Is Lexeo Therapeutics Inc. a candidate for recovery playBond Market & Free Community Consensus Stock Picks - newser.com
Why Lexeo Therapeutics Inc. stock is in analyst buy zoneJuly 2025 Reactions & Community Supported Trade Ideas - newser.com
Therapeutics Company Advances Gene Therapy Breakthrough - streetwisereports.com
Lexeo Therapeutics reports on LX2006 approval pathway - MSN
Chardan Raises Price Target on Lexeo Therapeutics to $17 From $15, Keeps Buy Rating - MarketScreener
HC Wainwright & Co. Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Leerink Partners Issues Positive Forecast for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In - Stocktwits
Chardan Capital Maintains Lexeo Therapeutics (LXEO) Buy Recommendation - Nasdaq
Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback (NASDAQ:LXEO) - Seeking Alpha
Lexeo, FDA position Friedreich ataxia therapy for accelerated path - BioWorld MedTech
Positive Outlook for Lexeo Therapeutics: Regulatory Advancements and Promising LX2006 Data Boost Stock Target - TipRanks
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - Stocktwits
Lexeo says FDA open to speedier approval of rare disease gene therapy - BioPharma Dive
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment - MarketScreener
Lexeo up after regulatory update on ataxia drug (LXEO:NASDAQ) - Seeking Alpha
Lexeo’s gene therapy for Friedreich ataxia shows promising results By Investing.com - Investing.com Canada
Lexeo Therapeutics Advances FDA Discussions for LX2006 - TipRanks
Lexeo Therapeutics announces progress in FDA discussions for LX006 in Friedreich ataxia cardiomyopathy - MarketScreener
Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway for LX2006 in Friedreich Ataxia with Promising Interim Data - Quiver Quantitative
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy - The Manila Times
Lexeo Therapeutics Announces Progress In FDA Discussions For LX006 In Friedreich Ataxia Cardiomyopathy - TradingView
23% LVMI reduction at 12 months — Lexeo's LX2006 shows cardiac & neurologic improvement; FDA open to pooling - Stock Titan
Can a trend reversal in Lexeo Therapeutics Inc. lead to recoveryJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Is Lexeo Therapeutics Inc. stock a top momentum playRate Hike & Daily Growth Stock Investment Tips - newser.com
Can Lexeo Therapeutics Inc. recover in the next quarterDip Buying & Verified Swing Trading Watchlist - newser.com
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Robertson Jenny | Chief Legal Officer |
Aug 18 '25 |
Sale |
4.67 |
542 |
2,530 |
62,556 |
| Adler Eric | Chief Medical Officer |
Aug 18 '25 |
Sale |
4.67 |
608 |
2,838 |
67,073 |
| Townsend Richard Nolan | Chief Executive Officer |
Aug 18 '25 |
Sale |
4.67 |
2,735 |
12,767 |
220,058 |
| See Tai Sandi | Chief Development Officer |
Aug 18 '25 |
Sale |
4.67 |
382 |
1,783 |
58,860 |
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):